Flynn, Robert W. V.
MacDonald, Thomas M.
Chalmers, James D.
Schembri, Stuart
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 12 October 2018
Accepted: 3 December 2018
First Online: 12 December 2018
Ethics approval and consent to participate
: All data were anonymised according to standard operating procedures (SOPs) as agreed by Tayside Committee on Research Medical ethics, Tayside Caldicott Guardians and research governance.
: Not applicable
: RF has received research grants from Novartis and GlaxoSmithKline.JC has received research grants from Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline and Pfizer. JC has also received fees for consultancy and speaking from Boehringer Ingelheim.TMM holds research grants from Novartis, Amgen, Ipsen, Teijin & Menarini. He has been the Principal Investigator on trials paid for by Novartis, Ipsen, Teijin, GlaxoSmithKline and Menarini. In the last 3 years he has been paid consulting fees by Novartis.Over the last 5 years SS has received funding from GlaxoSmithKline, Chiesi, Napp and Boehringer Ingelheim to attend meetings. He has been a consultant to Chiesi, Novartis, GlaxoSmithKline and Bayer. SS is or has been the principal investigator on trials paid for by: GlaxoSmithKline, Novartis, Oncimmune and Nycomed.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.